Board summary
Key figures
76,181
Registered population
58.8% aged 18–64
22.5%
Aged 65+
ICB 19.0% · England 17.9%
3.7%
Ethnic minority (non-White)
1.6% Asian · England 9.6%
6.8%
In IMD quintile 1
ICB 31.9% · England 21.0%
~5,032
Core20 residents (est.)
Resident basis; registered basis ~5,575 · see page 3
13,974
Hypertension register
+6.84% in 3 yrs · England +5.60%
681
SMI register
18.1% of Cheshire West and Chester (LAD)'s
1,796
COPD register
Reviews -11.65% in 3 yrs
Forecast to 2030
16,503
Hypertension patients, 2030
+2,529 on today
66.8%
QRISK ≥20% on statins, 2030
+3.28pp over 3 yrs
5.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure control fell over three years.
Control is 62.9% (England 67.8%) after falling 16.1% from 2023 to 2025 (England +3.2%); 80+ control is 72.9% (England 81.2%).
Estimated asthma patients without an annual review.
Asthma review coverage is 63.6% (England 65.7%) and fell 14.7% over 2023 to 2025 (England +4.4%), leaving about 1,900 of 5,111 unreviewed.
Vaccination and cervical screening exceed England rates.
In Q1 2025/26, 24-month MMR1 and 6-in-1 reached 97.0% and age-5 MMR2 95.9% (target 95.0%); cervical screening (ages 25-49) is 73.3% (England 66.8%).
Population, age and ethnicity
An older population with 22.5% aged 65 and over may shape local clinical need
Northwich PCN serves 76,181 registered patients. The PCN has an older age profile: 22.5% (17,119 patients) are aged 65 and over, compared with 20.3% in Cheshire West and Chester (LAD), 19.0% across NHS Cheshire and Merseyside Integrated Care Board, and 17.9% in England. Census usual residents in associated areas are 96.3% White (LAD 95.3%, ICB 93.0%, England 81.1%) and 3.7% ethnic minority, including 1.6% Asian or Asian British. This older demographic may drive higher demand for chronic disease care; ethnicity figures reflect Census residents, not registered patients.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Overall Core20 deprivation is low but practice rates span 16.4 pp
Core20 share is 6.8%, though the weighted practice share is 7.3% across unconfirmed observation periods. Both sit below Cheshire West and Chester (15.7%), NHS Cheshire and Merseyside ICB (31.9%) and England (21.0%), with an average IMD decile of 6.7 (borough 6.3, ICB 5.2, England 5.5). Practice shares span 16.4 pp: Middlewich Road Surgery has the highest concentration at 16.4% (1,202 estimated patients), while Danebridge Medical Centre has the largest volume at 1,974 estimated patients (8.2%). Estimated resident Core20 population is 5,032 across 3 decile-2 LSOAs.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
681
SMI register
0.89% recorded prevalence
418
Learning disability register
0.55% recorded prevalence
15
Care homes, 663 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
Recorded prevalence is 0.6% (418 patients) for learning disability (LAD 0.5%, ICB 0.6%, England 0.6%) and 0.9% (681 patients) for severe mental illness (LAD 1.0%, ICB 1.1%, England 1.0%). Catchment care homes comprise 15 sites (663 beds), though beds do not establish registered residents.
Severe mental illness: physical health checks
Severe mental illness prevalence is 0.9%. Blood pressure checks reached 79.8%, trailing England (83.4%) after falling 1.0 pp over 2023 to 2025 (England +4.4 pp). BMI checks reached 83.2% (England 82.1%). This gap could reflect recall capacity, testable by audit.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
13,974
Hypertension register
+6.84%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
−12.08pp
BP control, under 80
≤140/90 · −3.42pp aged 80+
+2,529
More patients by 2030
Forecast 16,503 (20.89%)
Hypertension case-finding and control
Hypertension prevalence is 18.3% (13,974 patients), above Cheshire West and Chester (17.0%), the ICB (16.8%) and England (15.2%). Blood pressure control for patients aged under 80 is 62.9%, trailing Cheshire West and Chester (66.3%), the ICB (66.4%) and England (67.8%), and fell 16.1% over 2023 to 2025 (England +3.2%). Recent blood pressure checks reached 85.4% (England 90.0%), and control in patients aged 80 and over is 72.9% (England 81.2%). This lower control could reflect recall capacity, testable by recall audit. Lower clinical control leaves more hypertensive patients above threshold than nationally, making recall audits and medication titration the clinical priority.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid lowering therapy reached 59.6%, below Cheshire West and Chester (63.8%), the ICB (63.2%) and England (63.6%). Among CKD patients, lipid lowering coverage is 66.3% (England 70.3%). Fewer high-risk patients receive lipid-lowering therapy than nationally, making primary prevention initiation the key opportunity.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 181,456 | £1.20 | £1.71 | £1.86 | £217,747 |
| Cardiovascular (all), 2025 | 252,850 | £3.21 | £4.37 | £3.33 | £811,648 |
In 2026, the PCN prescribed 181,456 lipid-regulating items at £1.20 per item, below Cheshire West and Chester (£1.44), the ICB (£1.71) and England (£1.86), spending £119,761 less than at England's unit cost. Lower unit expenditure than nationally provides headroom if practices expand lipid-regulating therapy to eligible high-risk patients.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−14.73%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.44%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.1% (5,111 patients) and COPD prevalence is 2.4% (1,796 patients), both above England (6.6% and 1.9%). Over 2023 to 2025, asthma reviews dropped 14.7% to 63.6% (England rose +4.4% to 65.7%), leaving about 1,900 patients unreviewed, while COPD reviews fell 11.7% to 68.0% (England rose +2.8% to 76.4%). Practice COPD prevalence spans from 2.0% at Oakwood Medical Centre to 3.1% at Middlewich Road Surgery. Declines could reflect review capacity, testable by recall audit.
Cancer register and children's immunisation
Cancer prevalence is 4.8% (3,646 patients), above England (3.8%). Childhood immunisation is high: age-5 MMR2 is 95.9% and 24-month MMR1 is 97.0%, both meeting the 95.0% target. However, 12-month 6-in-1 is 94.9% and age-5 4-in-1 is 94.1%. Same-cohort age-five MMR dose differences reach 12.5 pp at Watling Street Surgery and 7.1 pp at Witton Street Surgery.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage were diagnosed at stage 1 or 2 (7,482 of 13,490; England 55.3%), 19.5 pp below the 75.0% national ambition (requiring about 2,640 extra early-stage cases). Known-stage coverage was 72.8% (13,490 of 18,522; England 67.0%), describing the wider system rather than PCN performance. In primary care, PCN cervical screening coverage is 73.3% (England 66.8%), but fell 3.3% over 2023 to 2025 (England -1.0%), dropping to 66.4% at Watling Street Surgery and 67.8% at Witton Street Surgery. Screening declines at lower-coverage practices could delay early cancer detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For cancer waiting times in Jul 2026 (provisional), Mid Cheshire Hospitals NHS Foundation Trust met the 75.0% faster diagnosis standard at 80.0%, compared with North Cheshire and Mersey NHS Foundation Trust (80.2%), Manchester University NHS Foundation Trust (80.1%), England (79.3%), and NHS Cheshire and Merseyside Integrated Care Board (77.2%). For the 85.0% 62-day referral to treatment standard, Mid Cheshire achieved 71.1%, trailing North Cheshire and Mersey (83.7%), the ICB (76.2%), Manchester University (72.8%), and England (71.2%). These hospital operational metrics describe secondary care pressure across the local acute system, not PCN performance.
| Pathways within standard (%) | Mid Cheshire | North Cheshire and Mersey | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 79.95 | 80.21 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 86.21 | 98.17 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 71.12 | 83.67 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mid Cheshire | North Cheshire and Mersey | Manchester | England |
|---|---|---|---|---|
| MRI | 5.15 | 0.53 | 11.68 | 21.40 |
| CT | 1.09 | 2.32 | 14.66 | 9.92 |
| Echocardiography | 5.51 | 28.04 | 4.91 | 28.48 |
| Colonoscopy | 30.34 | 15.98 | 4.51 | 30.83 |
| Gastroscopy | 31.89 | 20.24 | 29.35 | 29.02 |
| All 15 DM01 tests | 12.72 | 6.34 | 8.98 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In Jun 2026 (provisional), community health service contacts for Cheshire West and Chester borough residents totaled 47,655. Contacts with adults aged 65 and over accounted for 52.7% of this activity (25,095 contacts). These figures reflect local authority resident demand across wider community intermediate and rehabilitation pathways rather than PCN-level activity.
Practice variation and patient experience
Practice phone contact ease spans 45.0 percentage points across Northwich PCN
Overall QOF achievement was 88.9% at Oakwood Medical Centre, compared with 92.5% for England. Achievement was 100.0% at Firdale Medical Centre and 100.0% at The Weaverham Surgery. Vaccination and immunisation achievement spanned 45.0 pp, from 55.0% at Middlewich Road Surgery to 100.0% at Firdale Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Firdale | 108 | 2.5 | 74.4% | 70.8% | 91.7% |
| Witton Street | 108 | 12.9 | 77.3% | 72.2% | 81.3% |
| Weaverham | 105 | 0.0 | 60.9% | 68.5% | 79.8% |
| Watling Street | 118 | 11.0 | 49.7% | 71.1% | 78.3% |
| Middlewich Road | 103 | 16.4 | 57.8% | 79.2% | 77.8% |
| Danebridge | 105 | 8.2 | 32.3% | 51.4% | 71.3% |
| Oakwood | 99 | 0.0 | 46.4% | 71.8% | 65.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen measures trail England, led by falling blood pressure control and respiratory reviews
Over 2023 to 2025, 15 of 25 compared measures trailed England. Under-80 blood pressure control fell 16.1% (England +3.2%), reaching 62.9% (England 67.8%), while asthma reviews fell 14.7% to 63.6% (England +4.4%) and COPD reviews fell 11.7% to 68.0% (England +2.8%). Hypertension treated to target fell 8.4% to 64.2% (England +3.6%). Conversely, heart failure reviews grew +17.4% to 72.8% (England +8.7%), and diabetes statin treatment with past CVD rose +3.0% (England +1.0%). Slower review delivery could reflect recall capacity, which a recall audit could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BP control, under 80
Asthma reviews
COPD reviews
Hypertension treated to target
BP control, 80+
Heart failure reviews
Diabetes statin (no CVD)
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 15 (663 beds) | n/a | Schools (catchment) | 71 | n/a |
| Children's centres | 3 | 15 | Places of worship | 54 | 231 |
| Libraries | 3 | 16 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 14 | 70 |
| Primary academies | 15 | 46 | Special schools | 1 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD review recall
Asthma reviews fell 14.7% over 2023 to 2025 to 63.6% (England +4.4% to 65.7%), leaving 1,861 (about 1,900) of 5,111 patients unreviewed; COPD reviews fell 11.7% to 68.0% (England 76.4%; 1,796 patients, 2.4%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension control and lipid therapy recall
Under-80 BP control is 62.9% (England 67.8%), falling 16.1% over 2023 to 2025 (England +3.2%) across 13,974 hypertension patients (18.3%); QRISK ≥ 20% lipid therapy is 59.6% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Two-track Core20 outreach and phone audit
Practice Core20 shares span 16.4 pp (up to 16.4%, 1,202 estimated patients; largest volume 1,974 at 8.2%), GPPS phone ease spans 45.0 pp (32.3% to 77.3%; England 56.9%), and SMI BP checks are 79.8% (England 83.4%). Low cost, quick to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | — | PCN |
| Primary care phone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and COPD review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension control and lipid therapy recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Two-track Core20 outreach and phone audit (p12) | Core20 cohort (IMD quintile 1) · GPPS easy to contact the practice by phone · GPPS last request led to a booked appointment | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
